Breaking News, Collaborations & Alliances

Evotec Earns Boehringer Research Milestone

Oncology molecule moves to Phase I trials

Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim triggering a €2.0 million payment to Evotec. The milestone was for the transition of an oncology molecule into Phase I clinical trials.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, “This is a very important 19th milestone for Evotec in our collaboration with Boehringer Ingelheim, as it represents the first oncology compound to progress into Phase I studies. The collaboration continues to drive value for both companies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters